In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.
APG-1387 Overview
APG-1387 is being developed to treat advanced solid tumors, including nasopharyngeal cancer, advanced pancreatic ductal adenocarcinoma, advanced non-small cell lung cancer, colorectal cancer, blood cancers, pancreatic cancer, peritoneal carcinomatosis (peritoneal cancer) and hepatitis B. It is being developed to treat head and neck cancers, leukemias and lymphomas. The drug candidate is a new chemical entity that is administered via intravenous and parenteral routes. The drug candidate works by targeting inhibitors of apoptosis proteins (IAPs).
International Overview of Ascentage Pharmaceutical Group
Ascentage Pharma (Ascentage) is a biotechnology company dedicated to the discovery and development of targeted small molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It develops therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company’s product lines include HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma’s lead product candidate, HQP8361, is a second-generation c-Met kinase inhibitor for the treatment of c-Met-positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. The company has R&D centers and production facilities in Hong Kong, China and the United States. Ascentage Pharmaceuticals is headquartered in Suzhou, Jiangsu, China.
For complete information on APG-1387 drug-specific PTSR and LoA scores, purchase the report here.
Desde
The gold standard in business intelligence.
GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.
GlobalData, a leading provider of industry intelligence, provided the underlying data, research and analysis used to write this article.
GlobalData’s Likelihood of Approval Analysis tool dynamically assesses and predicts the likelihood of a drug advancing to the next phase of clinical development (PTSR), as well as the likelihood of drug approval (LoA). This is based on a combination of machine learning and proprietary algorithms used to process data points from various databases in GlobalData’s Pharmaceutical Intelligence Center.